Dr Uhlen received his PhD in chemistry at the Royal Institute of Technology (KTH), Stockholm, Sweden in 1984. After a post-doc period at the EMBL in Heidelberg, Germany, he became professor at KTH in 1988. His research has resulted in more than 800 peer-reviewed publications leading to more than 120,000 academic citations with an h-index of 147 (Google Scholar). His focus in science has been technology- and data-driven research, involving protein science, antibody engineering, AI-based systems biology and precision medicine. A list of selected scientific achievements are shown below.
Dr Uhlen has been the Director of the Human Protein Atlas program since the launch in 2003 and was the Founding Director the Science for Life Laboratory (SciLIfeLab) between 2010 and 2015. He is member of the Royal Swedish Academy of Engineering Science (IVA), the Royal Swedish Academy of Science (KVA), the National Academy of Engineering (NAE) in USA and the European Molecular Biology Organization (EMBO). He was the President of the European Federation of Biotechnology (EFB) from 2015 to 2019 and he was the Vice-President of the Royal Institute of Technology (KTH) from 1999 to 2001. He is the co-initiator of the annual KTH Innovation Award established in 2020 and the Science and SciLifeLab Prize for Young Scientists established in 2013. He is Honorary Doctor at Chalmers University, Sweden (2011) and Rouen University, France (2020).
Dr. Andreas Greinacher, specialized in transfusion medicine, immunohematology and hemostasis, had been full professor and head of the department of transfusion medicine at the Universitätsmedizin Greifswald, Germany until 2024, where he is now associated as senior professor. His research interests are hereditary and immune-mediated platelet disorders, especially heparin-induced thrombocytopenia and application of biophysics to understand molecular mechanisms of antigenicity of endogenous proteins. He has identified the genetic basis of the HNA-3a antigen, an important cause of TRALI, developed a new, immune based, treatment approach for hemolytic uremic syndrome during the EHEC outbreak in Germany in 2011, and contributed to better understanding of heparin-induced thrombocytopenia. In the 1990s, he was the principal investigator of the studies leading to international approval of recombinant hirudin as the first non-heparin/warfarin anticoagulant. Since 2021, his work on vaccine-induced immune thrombotic thrombocytopenia (VITT) received major attention by the scientific community and the general public, with the most recent identification of VITT-like disorders after (viral) infections and associated with monoclonal gammopathy as causes of severe, recurrent venous and arterial thrombosis.
Over more than 20 years he had been in various functions, Chief of Staff and CEO of the University Hospital Greifswald or Associate Dean of the Medical faculty. He has published more than 600 papers on these topics (Google Scholar H-index 114) and has received several national and international awards including the Award of Analytical Biochemistry of the DGKL in 2022.
Frau Priv.-Doz. Dr. med. Linda Schönborn ist Clinician Scientist und Ärztin am Institut für Transfusionsmedizin der Universitätsmedizin Greifswald. Nach dem Studium der Humanmedizin in Greifswald promovierte sie dort mit summa cum laude und habilitierte sich 2025 im Fach „Experimentelle Transfusionsmedizin“.
Ihre wissenschaftlichen Schwerpunkte liegen auf Anti-Plättchenfaktor-4-(PF4)-Antikörper-assoziierten Immunthrombosen, insbesondere der Heparin-induzierten Thrombozytopenie (HIT) und der Vakzin-induzierten Immunthrombozytopenie und Thrombose (VITT), sowie auf Fragestellungen der Blutversorgung im demographischen Wandel.
Während der COVID-19-Pandemie betreute sie gemeinsam mit ihrem Team deutschlandweit Patientinnen und Patienten mit Vakzin-induzierter Immunthrombozytopenie mit Thrombose (VITT). In den Folgejahren identifizierte die Arbeitsgruppe zudem postvirale VITT-Fälle und untersuchte die zugrunde liegenden immunologischen Mechanismen. Gemeinsam mit internationalen Kollaborationspartnern gelang es, wesentliche Aspekte der Pathogenese der VITT aufzuklären und damit Grundlagen für die zukünftige Entwicklung sichererer adenovirusbasierter Impfstoffe zu schaffen. Für ihre Forschungsarbeiten wurde Frau Dr. Schönborn unter anderem mit dem Langener Wissenschaftspreis des Paul-Ehrlich-Instituts, dem Jean Julliard Prize der ISBT sowie dem Preis der Stiftung „Diagnostik hilft“ ausgezeichnet. Ihre Forschung wird u.a. durch Förderungen der Deutschen Forschungsgemeinschaft (DFG), der American Society of Hematology (ASH) und der Else Kröner-Fresenius-Stiftung unterstützt.
Prof. Dr. Christian G. Schroer ist Leitender Wissenschaftler am Deutschen Elektronen-Synchrotron DESY in Hamburg und Professor für „X-Ray Nanoscience and X-Ray Optics“ an der Universität Hamburg. DESY ist ein Forschungszentrum der Helmholtz-Gemeinschaft und betreibt große Beschleuniger- und Röntgenlichtquellen, an denen Forschende aus vielen Disziplinen Materie mit besonders intensivem und präzise gebündeltem Röntgenlicht untersuchen.
Christian Schroer ist wissenschaftlicher Leiter der Synchrotronstrahlungsquelle PETRA III, einer der leistungsfähigsten Röntgenlichtquellen weltweit für harte Röntgenstrahlung. Seine Forschung gilt der Entwicklung moderner Röntgenmikroskopie und Röntgenoptik — also Methoden, mit denen sich Strukturen und Prozesse sichtbar machen lassen, die für konventionelle Mikroskope nicht zugänglich sind. Anwendungen reichen von Physik, Chemie und Materialwissenschaften bis zu Lebenswissenschaften, Nanotechnologie und
Kulturwissenschaften.
Schroer studierte Physik an der RWTH Aachen und promovierte in theoretischer Physik an der Universität zu Köln. Nach Forschungsstationen am Forschungszentrum Jülich, an der University of Maryland und an der RWTH Aachen wechselte er 2004 zu DESY. Von 2006 bis 2014 war er Professor für Strukturphysik kondensierter Materie an der Technischen Universität Dresden. Seit 2014 ist er Leitender Wissenschaftler bei DESY und Professor an der Universität Hamburg. In seiner Arbeit verbindet er Grundlagenforschung, Instrumentenentwicklung und neue Bildgebungsmethoden für große Forschungsinfrastrukturen.
Personal Data
| Title | Prof. Dr. med. |
| First name | Klaus |
| Name | Pantel |
| Date of birth | 3. August 1960, male |
| Current position | Professor, Director, Institute of Tumor Biology |
| Current institution | Universitätsklinikum Hamburg-Eppendorf Hamburg, Martinistraße 52, 20246 Hamburg |
| Phone | +49 7410 53503 |
| pantel@uke.de |
Academic Education and Graduation
| 1995 | Habilitation in Immunology, LMU Munich |
| 1987-1989 | DFG-Postdoctoral fellow, Wayne-State University, Detroit, USA |
| 1985-1987 | Dr. med. thesis, University Cologne Subject: Mathematical Modeling |
| 1980-1986 | Studies of Medicine, University Cologne |
Professional Career
| Since 2019 | Founder and Chairman of the European Liquid Biopsy Society (ELBS) |
| 2016-2023 | Adjunct Professor of Medicine, University of Bergen, Norway |
| Since 2015 | Member of the Executive Board of the University Cancer Center Hamburg |
| Since 2002 | Director & C4 Professor, Institute of Tumor Biology, UKE, Hamburg, Germany |
| 1999-2002 | C3 Professor, Molecular Genetics in Gynaecology, UKE (Germany) |
| 1989-1998 | Faculty Researcher, Group leader, Institute of Immunology LMU Munich |
Academic Distinctions and leadership (selection)
| 2023 | Coordinator of the Cancer Mission EU Network project PANCAID |
| 2023 | Coordinator of the EU/IHI consortium GUIDE.MRD |
| 2020 | Founder & Coordinator of the ELBS consortium (www.elbs.eu) |
| 2019 | ERC (European Research Council) Advanced Investigator Grant Award INJURMET |
| 2014 | ERC (European Research Council) Advanced Investigator Grant Award DISSECT |
| 2015 | Coordinator of the EU/IMI Network CANCER-ID |
| Since 2017 | Member of the Steering Committee of the DFG SPP µBONE |
| 2010 | AACR Outstanding Investigator Award for Breast Cancer Research, San Antonio, USA |
| 2010 | German Cancer Award 2010 (Translational Area), Berlin |
| 2026 | PMWC Pioneer Award, Silicon Valley, Santa Clara, USA |
Third Party Funding (selection)
| Short title of the project | Funding Institution | Time period | Volume [€] |
| PANcreatic CAncer Initial Detection via liquid biopsy (PANCAID) | EU Horizon Europe | 01/2023-12/2027 | 9 845 090 € (UKE: 1.8 mio €) |
| GUIding multi-moDal thErapies against MRD by liquid biopsies (GUIDE.MRD) | IHI EU | 05/2023-04/2028 | 34 452 565 € (UKE: 2.3 mio €) |
| Impact of tissue injury induced by diagnostic biopsies and surgery on cancer metastasis (INJURMET) | European Research Council (ERC) | 2019-2025 | 2 500 000 € |
| Fleur Hiege-Centrum für Hautkrebsforschung | Hiege Stiftung - die Deutsche Hautkrebsstiftung | 10/2022-09/2027 | 1 000 000 € |
| European Liquid Biopsy Society (ELBS) | International private-public partnership network | 2019- present | |
| Priority program: uBONE SPP2084: RAI2 as novel suppressor of cancer cell homing and survival in the bone marrow | DFG | 07/2018-06/2021 | 385 348€ |
| Predicting Treatment Response in Carcinoma of Unknown Primary (CUP) by Multiscale In-Depth Molecular Profiling within the Frame of a Clinical Immune Oncology Trial (CUPIDO) | Deutsche Krebshilfe Priority Program: Translational Oncology | 08/2023- 07/2026 | 1 195 355 € |
| DETECT-CTCHIGH: Subproject 5: Unravelling novel mechanisms of resistance to targeted therapy in HR-positive metastatic breast cancer by molecular characterization of circulating tumor cells | Deutsche Krebshilfe | 07/2022-06/2025 | 324 627 € |